News roundup Tuesday, November 19

The latest from BioStock

» BiBBInstruments founder about the evaluation at Sahlgrenska
» Can we reverse diabetes? – Abarceo Pharma wants to develop the solution of the future
» Curasight selects brain cancer as first indication for uTREAT
» Respiratorius CEO: "Continuing to reduce the risk in the project"
» Alzinova on the way to the next phase in Alzheimer's

Read the newsletter for v.46 here.

Do not miss BioStock Life Science Summit 2024 November 20-21 at Medicon Village in Lund!

The latest news

SEK 43,4 million is raised in a heavily oversubscribed rights issue including the exercise of an over-allotment option. Read more.

Neola Medical secures US trademark for the Neola logo ahead of market launch. Read more.

Iconovo announces preliminary outcome of rights issue. Read more.

Modus Therapeutics receives approval to start a Phase IIa clinical trial for chronic kidney disease. Read moreThe company has also secured access to bridge financing of up to SEK 5 million from its largest shareholder, Karolinska Development. Read more.

Spermosis provides an update on how the clinical study is progressing. Read more.

SensoDetect sees new business after Medica in Düsseldorf 2024. Read more.

Bio Vitos Pharma The first participants are invited to clinical trials. Read more.

Novo Nordisk informs about share repurchase programs. Read more.

Thor Medical sends the first product sample to potential customer from Herøya pilot facilities. Read more.

Lumitos TO6 was subscribed to approximately 94 percent and will provide the company with approximately SEK 12,6 million. Read more.

Observe Medical announces an increase in share capital in connection with an offering and conditional conversion of loans. Read more.

S2Medical announces that Epiprotect's sales are expected to at least triple in 2024 – with the aim of continued growth during the year. Read moreThe company also clarifies the transition to semi-annual financial reporting. Read more.

DanCann Pharma announces that the Danish government is proposing a permanent system for prescription medical cannabis for Danish patients. Read more.